Alnylam Pharmaceuticals Gains Advantage After Competitor's Trial Failure
The recent failure of a rival's clinical trial has unexpectedly bolstered Alnylam Pharmaceuticals' outlook for its TTR franchise, leading to increased investor confidence.
Editorial Staff 5 days ago